(Reuters) -Eli Lilly (LLY) raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro helped it beat third-quarter earnings estimates. The company shares rose 2% in early morning trading on Thursday. Lilly competes with Novo Nordisk for the top spot in the weight-loss drug market, which is poised to reach $150 billion by the end of the decade. Investors have been keenly awaiting latest results from the drugma ...